HIGH POINT, N.C.--(BUSINESS WIRE)--
vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT) today announced that data on the company’s phase 3 Alzheimer’s candidate, azeliragon, an oral antagonist of the Receptor for Advanced Glycation Endproducts (RAGE), will be presented at the 2017 Alzheimer's Association International Conference (AAIC) held in London, England, July 16 – 20, 2017.
Details of the poster presentations are listed below:
Poster Title: “Assessment of Azeliragon QTc Liability through
Integrated, Model-Based Concentration QTc Analysis”
Poster
Number: P1-066
Category: Therapeutics: Clinical
Date
and Time: Sunday, July 16, 2017, 9:30 am – 4:15 pm GMT
Location:
S8
Poster Title: “Effect of Food on the Pharmacokinetics of
Azeliragon in Healthy Adult Subjects”
Poster Number: P2-025
Category:
Therapeutics: Clinical
Date and Time: Monday, July 17, 2017,
9:30 am – 4:15 pm GMT
Location: S8
About Azeliragon
Azeliragon, also known as TTP488, is a novel orally active small-molecule antagonist of RAGE. A broad range of human pathologic and experimental biologic investigation suggests that RAGE activation contributes to the pathogenesis of Alzheimer’s disease. Sustained Amyloid-β interactions with RAGE at the blood-brain barrier (BBB) and in neuronal and microglial cells, play potentially major roles in amyloid plaque formation, neuroinflammation and chronic neural dysfunction – all hallmarks of Alzheimer’s disease.
About vTv Therapeutics
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer’s disease and Type 2 diabetes as well as treatment of inflammatory disorders and the prevention of muscle weakness.
Forward-Looking Statements
This release contains forward-looking statements, which involve risks and uncertainties. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and, in each case, their negative or other various or comparable terminology. All statements other than statements of historical facts contained in this release, including statements regarding the timing of our clinical trials, our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause our results to vary from expectations include those described under the heading “Risk Factors” in our Annual Report on Form 10-K and our other filings with the SEC. These forward-looking statements reflect our views with respect to future events as of the date of this release and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date of this release and, except as required by law, we undertake no obligation to update or review publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this release. We anticipate that subsequent events and developments will cause our views to change. Our forward-looking statements do not reflect the potential impact of any future acquisitions, merger, dispositions, joint ventures or investments we may undertake. We qualify all of our forward-looking statements by these cautionary statements.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170713006088/en/
